Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

MAP 2018 - Banner

The MAP congress is a one-of-a-kind meeting designed by a faculty of highly influential key opinion leaders to answer the need on how to integrate in daily practice the wealth of information coming from the analysis of tumour samples. 

Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and UNICANCER are the organisers of this annual forum where the understanding of the tumour microenvironment as well as the impact of macroevolution and their connection to treatment resistance is a significant field of discussion in personalised medicine. New models, technologies, the current treatment advances available and new findings of ongoing clinical trials are vital to understanding which molecular alterations should be the object of therapeutic targets in cancer treatment. 

Fast Facts: MAP 2018

  • Expecting over 400 participants
  • No parallel sessions
  • Possibility to host a satellite symposium
  • More than 28 key opinion leaders
  • Excellent networking opportunities 

How can I participate in the MAP 2018?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress. 

For sponsorship information and a prospectus please contact:

Jon Roberts

Head of Strategic Partnerships


We look forward to hearing from you!

Who has already signed up?

ESMO gratefully acknowledges the valuable contribution of the following organisations in the ESMO MAP 2018 Congress through their presence in the exhibition hall, organisation of sponsored sessions, or via sponsorship activities (As of August 2018):

Founding Partners


Bayer logo 2018

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes now four marketed products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Roche-Foundation Medicine

Foundation Meidicine Roche Logo

Roche, the world’s largest biotech company, leader in research-focused healthcare with strength in diagnostics, and Foundation Medicine a molecular information company are joining forces to help cancer patient with access to personalized care, providing an informative comprehensive genomic profiling (CGP) assay to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials.

Platinum Sponsor


illumina logo

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. For further details please visit our website.

Start-up Contributor

TESARO Bio France

Tesaro Logo

TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. TESARO sees new possibilities to responsibly develop and commercialize innovative treatments where others may not.
For TESARO, Relationships are vital to the success of its activities, and the company commits to be a trusted partner to the cancer community

Start-up Associate

Incyte Biosciences International Sàrl

Incyte Logo

Incyte is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's web site.


oncoDNA Logo

OncoDNA helps oncologists select better treatments for patients. It combines advanced, comprehensive testing of disease biomarkers with a cancer treatment knowledge database which continuously ‘learns’ from scientific and medical advances. Four analyses are available: OncoDEEP®, OncoSTRAT&GO®, OncoTRACE™ and OncoSELECT®. Results report and follow-up data are accessible on the OncoSHARE® platform.

Educational Grant Supporters


Astra Zeneca Logo

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Bristol-Myers Squibb

Bristol Myers Squibb Logo 2015
Bristol-Myers Squibb (Headquarters: New York, CEO: Giovanni Caforio) is a global specialty biopharmaceutical company with more than 130 years of history, operating worldwide. With the mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, the company concentrates its R&D efforts on four key disease areas, “Oncology”, “Immunoscience”, “Cardiovascular” and “Fibrosis”.



At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Pfizer Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.